Google
NRXPW — NRX PHARMACEUTICALS INC
NRXPW FAQ
What is NRXPW's P/E ratio?
NRX PHARMACEUTICALS INC (NRXPW) currently trades at a P/E ratio of 1,985.03.
What is NRXPW's ROE?
NRX PHARMACEUTICALS INC reports a Return on Equity (ROE) of 177.63%.
What is NRXPW's dividend yield?
NRX PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is NRXPW's Deepscope Quality Score?
Deepscope rates NRXPW's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NRXPW?
Deepscope's AI Timing Score for NRXPW is 1 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 0.01
Price
0.00
(0.00%)
Day Change
|
|
|---|
NRXPW, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.01 |
| PBV / Sector |
-51.72 / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
1,985.03 / N/A
GREAT
|
| PEG or PE/Growth / Sector |
12.55 / N/A
|
| Average 1M Daily Value |
311.560355000000
|
| Average 1W Daily Value |
123.242800000000
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1201 N. Market Street, Wilmington, DE, United States, 19801
Phone: 484 254 6134
Website: https://www.nrxpharma.com
Sector: -
Description: NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
